Department of Internal Medicine and Medical Oncology, Cancer Research Institute, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-0934, Japan.
J Infect Chemother. 2009 Oct;15(5):316-21. doi: 10.1007/s10156-009-0702-z. Epub 2009 Oct 24.
We report a 48-year-old man with hepatocellular carcinoma (HCC) treated with hepatic arterial infusion (HAI) chemotherapy followed by proton beam therapy. The HCC lesion in this patient was 88 mm in diameter, with portal vein tumor thrombosis in the right lobe of the liver. He was first treated with 5-fluorouracil, cisplatin, and isovorin, administered by HAI, combined with interferon-alpha, and he was subsequently treated with epirubicin and mitomycin-C administered by HAI. However, no definite efficacy of either of these treatments was observed. Then, after 3 weeks' continuous administration of irinotecan by HAI, the tumor size decreased to 68 mm in diameter. However, 3 months after reduction of the tumor, the tumor had become enlarged to 100 mm in diameter and intrahepatic metastases were prominent. Angiographic findings indicated that the HCC was fed not only from the right hepatic artery but also from the left gastric and right and left subphrenic arteries. After rearrangement of the arteries, and 3 months' continuous HAI chemotherapy with irinotecan, plus hyperthermia, the tumor size had decreased to 50 mm in diameter. The reduction rate of the main tumor according to the Response Evaluation Criteria in Solid Tumors was 43%; therefore, the efficacy of this treatment was judged as a partial response. Two months after reduction of the tumor, the patient's serum alpha-fetoprotein (AFP) level was elevated, and so docetaxel was administered by HAI instead of irinotecan. The liver tumors showed gradual enlargement during the administration of docetaxel, although the AFP level was suppressed. Proton beam therapy was instituted and the liver tumors showed necrosis after this therapy. The patient died of hepatic failure and distant metastases 6 years after the onset of HCC. As far as we know, this is the first case report of HCC treated effectively with irinotecan administered by HAI followed by proton beam therapy in which tumor suppression and the long-term survival of the patient were observed.
我们报告了一例 48 岁男性肝细胞癌(HCC)患者,他接受了肝动脉灌注(HAI)化疗,随后接受了质子束治疗。该患者的 HCC 病变直径为 88 毫米,右叶肝门静脉有肿瘤血栓。他首先接受了 5-氟尿嘧啶、顺铂和伊立替康的 HAI 治疗,联合干扰素-α,随后接受了表柔比星和丝裂霉素-C 的 HAI 治疗。然而,这些治疗都没有明显效果。然后,在 HAI 持续 3 周输注伊立替康后,肿瘤大小缩小至 68 毫米。然而,在肿瘤缩小 3 个月后,肿瘤已增大至 100 毫米,肝内转移明显。血管造影结果表明,HCC 不仅由右肝动脉供血,还由胃左动脉、右膈下动脉和左膈下动脉供血。重新排列动脉后,伊立替康联合持续 3 个月的 HAI 化疗加高热治疗后,肿瘤大小缩小至 50 毫米。根据实体瘤反应评估标准,主肿瘤的缩小率为 43%;因此,该治疗的疗效被判断为部分缓解。肿瘤缩小 2 个月后,患者血清甲胎蛋白(AFP)水平升高,因此改用 HAI 给予多西他赛治疗。在给予多西他赛期间,肝肿瘤逐渐增大,尽管 AFP 水平得到抑制。给予质子束治疗后,肝肿瘤发生坏死。HCC 发病后 6 年,患者死于肝衰竭和远处转移。据我们所知,这是首例报道的 HAI 给予伊立替康治疗有效,随后接受质子束治疗的 HCC 病例,观察到肿瘤抑制和患者的长期生存。